PhD OPPORTUNITIES – Our Institute is always open to informal enquiries and will consider applications from prospective PhD students. If you have any queries about the research programmes (or potential PhD supervisors) within the Institute of Cellular Medicine (ICM), please feel free to contact me for further information. Email address: firstname.lastname@example.org
1/2/02-30/6/05 Senior Research Associate, University of Newcastle, (Wellcome Trust funded)
1/11/98-28/1/02 Research Associate, University of Newcastle (Action Research funded)
2001- The Endocrine Society, USA
2002- The RNA Society, USA
2002- ASBMB (American Society for Biochemistry and Molecular Biology)
2002- FASEB (Federation of American Societies for Experimental Biology).
2007-European parturition Group-EuPG.
2008- Society for Gynecologic Investigation (SGI).
I have worked extensively on alternative pre-mRNA splicing and the role of splicing factors (RNA-binding proteins) primarily using the human myometrium (uterine smooth muscle) as a model system.
We are now studying regulation and functional implications of cancer-associated alternative splicing events in breast cancer biology. Our work aims to help define how alternative splicing events change in different cancer subtypes and what impact these changes may potentially have on disease progression and drug resistance.
We are also interested in studying cellular and molecular mechanisms associated with activation of TLR signalling pathways; this research theme includes several active projects in reproductive medicine and TLR responses to metal ions.
12 Postgraduate students have graduated from my supervision since 2006 (4 PhD students and 8 MRes students). I am happy to consider applications from self-funded students.
MRC, Wellcome Trust, Action Medical Research, BBSRC, Wellbeing for Women, Breast Cancer Campaign.
Molecular Human Reproduction, Reproductive Sciences, Molecular Endocrinology PlosONE, FEBS letters.
Editorial Board: Advances in Molecular Biology (Hindawi Publishing).
mini-gene construction; transient and stable transfections; reporter assays; gene silencing techniques (RNAi and morpholinos); nuclear splicing assays; DNA and RNA mobility shift assays; protein: RNA-binding assays/iCLIP; immunoprecipitation; PCR (conventional and Real-time, Q-PCR arrays); TLR signalling assays.
Action Medical Research; Wellcome Trust; RVI Breast Cancer Appeal; Dr William Harker Foundation; The JGW Patterson Foundation; William Luccock and Ernest Jeffcock Foundation; Charles & Elsie Sykes Charitable Trust; Breast Cancer Campaign; Wellbeing for Women (WOW); Newcastle upon Tyne Hospitals NHS Trust; NIHR BRC; Gateshead Health National Health Service Foundation Trust.